Essex Property Trust (NYSE:ESS) reported quarterly earnings of $3.77 per share which beat the analyst consensus estimate of $1.45 by 160 percent. This is a 16 percent increase over earnings of $3.25 per share from the same period last year.
ImmunityBio Announces FDA Acceptance Of Biologics License Application For N-803 In BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. ((IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder
